C&Y Pharmaceutical Group

C&Y Pharmaceutical Group, formerly known as Shanxi Qianyuan Pharmaceutical, is a leading integrated healthcare enterprise in China specialized in the research, production, and distribution of chemical drugs, biological products, and nutritional supplements. Established in 2005 and headquartered in Shanghai, the company has been publicly listed on the Shenzhen Stock Exchange (300254) since 2011. Its diverse portfolio targets critical therapeutic areas such as cardiovascular disease, urology, respiratory health, and pediatrics, with notable commercial products including apixaban, rivaroxaban, and tamsulosin. Beyond pharmaceutical manufacturing, C&Y is distinguished by its foray into healthcare services, providing medical diagnostics and genetic preservation. The company maintains robust manufacturing capabilities with a focus on high-quality generic medications and active pharmaceutical ingredients (APIs).